Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-30), PhoenixBio Co's 9-Day RSI is 40.73.
The industry rank for PhoenixBio Co's 9-Day RSI or its related term are showing as below:
TSE:6190's 9-Day RSI is ranked worse than 76.76% of 1420
companies
in the Biotechnology industry
Industry Median: 40.575
vs TSE:6190: 40.73
PhoenixBio Co (TSE:6190) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PhoenixBio Co 9-Day RSI Related Terms
TSE:6190 vs VRTX, REGN, RVMD: 9-Day RSI Comparison
For the Biotechnology subindustry, PhoenixBio Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a 9-Day RSI of 40.73 as of Jul. 30, 2026. According to the industry distribution chart, PhoenixBio Co ranks #1090 out of 1420 companies in the Biotechnology industry, placing it in the top 76.8%.
Is PhoenixBio Co's 9-Day RSI too high?
PhoenixBio Co's current 9-Day RSI is 40.73. The Biotechnology industry median 9-Day RSI is 40.58. PhoenixBio Co's value of 40.73 is 0.4% above this industry median. Based on the distribution chart, PhoenixBio Co ranks #1090 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PhoenixBio Co has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #1090 out of 1420 companies for 9-Day RSI. This places PhoenixBio Co in the lower half of its industry. The industry median 9-Day RSI is 40.58. PhoenixBio Co's value of 40.73 is 0.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 40.58, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current 9-Day RSI of 40.73 is 0.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 40.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current 9-Day RSI is 40.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円355.40, compared to a current price of 円339.00 — trading 4.6% below its estimated fair value. The current 9-Day RSI is 40.73 and 0.4% above the Biotechnology industry median of 40.58. PhoenixBio Co's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current 9-Day RSI is 40.73 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円339.00 is trading 4.6% below its estimated GF Value™ of 円355.40.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
9-Day RSI: 40.73
GF Value™: 円355.40 vs. price of 円339.00 (4.6% below fair value)
Industry Position: 0.4% above the Biotechnology median (#1090 of 1420)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
56GF Score
Get the complete analysis for TSE:6190
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
